[go: up one dir, main page]

DE60006717D1 - Neue modulatoren der dopamin-neurotransmission - Google Patents

Neue modulatoren der dopamin-neurotransmission

Info

Publication number
DE60006717D1
DE60006717D1 DE60006717T DE60006717T DE60006717D1 DE 60006717 D1 DE60006717 D1 DE 60006717D1 DE 60006717 T DE60006717 T DE 60006717T DE 60006717 T DE60006717 T DE 60006717T DE 60006717 D1 DE60006717 D1 DE 60006717D1
Authority
DE
Germany
Prior art keywords
alkyl
oso
phenyl
disclosed
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60006717T
Other languages
English (en)
Other versions
DE60006717T2 (de
Inventor
Bengt Andersson
Clas Sonesson
Susanna Waters
Nicholas Waters
Joakim Tedroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurosearch Sweden AB
Original Assignee
A Carlsson Research AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Carlsson Research AB filed Critical A Carlsson Research AB
Publication of DE60006717D1 publication Critical patent/DE60006717D1/de
Application granted granted Critical
Publication of DE60006717T2 publication Critical patent/DE60006717T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
DE60006717T 1999-12-22 2000-12-22 Neue modulatoren der dopamin-neurotransmission Expired - Fee Related DE60006717T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9904724A SE9904724D0 (sv) 1999-12-22 1999-12-22 New modulators of dopamine neurotransmission I
SE9904724 1999-12-22
PCT/SE2000/002673 WO2001046144A1 (en) 1999-12-22 2000-12-22 New modulators of dopamine neurotransmission

Publications (2)

Publication Number Publication Date
DE60006717D1 true DE60006717D1 (de) 2003-12-24
DE60006717T2 DE60006717T2 (de) 2004-08-12

Family

ID=20418253

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60023345T Expired - Lifetime DE60023345T2 (de) 1999-12-22 2000-12-22 Neue modulatoren der dopamin-neurotransmission
DE60006717T Expired - Fee Related DE60006717T2 (de) 1999-12-22 2000-12-22 Neue modulatoren der dopamin-neurotransmission
DE60045395T Expired - Lifetime DE60045395D1 (de) 1999-12-22 2000-12-22 1-Phenylpiperazin-Derivaten als Modulatoren der Dopamin-Neurotransmission

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60023345T Expired - Lifetime DE60023345T2 (de) 1999-12-22 2000-12-22 Neue modulatoren der dopamin-neurotransmission

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60045395T Expired - Lifetime DE60045395D1 (de) 1999-12-22 2000-12-22 1-Phenylpiperazin-Derivaten als Modulatoren der Dopamin-Neurotransmission

Country Status (30)

Country Link
US (3) US6903120B2 (de)
EP (3) EP1428822B1 (de)
JP (3) JP4975928B2 (de)
KR (2) KR100690133B1 (de)
CN (2) CN1255382C (de)
AT (3) ATE254601T1 (de)
AU (2) AU2570401A (de)
BG (2) BG110211A (de)
BR (1) BR0016611B1 (de)
CA (1) CA2394602C (de)
CZ (1) CZ303302B6 (de)
DE (3) DE60023345T2 (de)
DK (1) DK1240142T3 (de)
EE (2) EE200900004A (de)
ES (2) ES2246926T3 (de)
HK (1) HK1054229B (de)
HR (2) HRP20050784A2 (de)
HU (1) HU229605B1 (de)
IL (3) IL150351A0 (de)
MX (1) MXPA02006320A (de)
NO (2) NO323436B1 (de)
NZ (2) NZ531680A (de)
PL (1) PL205093B1 (de)
RU (2) RU2265013C2 (de)
SE (1) SE9904724D0 (de)
SI (1) SI1240142T1 (de)
SK (1) SK287367B6 (de)
UA (1) UA73338C2 (de)
WO (2) WO2001046145A1 (de)
ZA (1) ZA200204812B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
PE20020690A1 (es) * 2000-11-03 2002-08-23 Upjohn Co Metodo y tratamiento y prevencion de los dolores de cabeza de migranas
JP2005511500A (ja) 2001-08-31 2005-04-28 ザ ロックフェラー ユニバーシティー 脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ１ｂ媒介シグナル伝達の調節
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
KR101245075B1 (ko) * 2004-06-08 2013-03-18 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
ATE449070T1 (de) 2004-06-08 2009-12-15 Nsab Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission
US7851629B2 (en) * 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
AU2005254726A1 (en) * 2004-06-18 2005-12-29 Neurosearch A/S Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MX2007004216A (es) * 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
HUE029790T2 (hu) * 2004-10-13 2017-04-28 Teva Pharmaceuticals Int Gmbh Eljárás 4-(3-metánszulfonil-fenil)-l-N-propil-piperidin elõállítására
US7923444B2 (en) 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20080269286A1 (en) 2005-12-07 2008-10-30 Clas Sonesson Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission
CN101400642A (zh) * 2006-03-10 2009-04-01 纽约州州立大学研究基金会 具有中枢神经系统活性的环丙烷
CA2667510A1 (en) * 2006-10-27 2008-06-12 Janssen Pharmaceutica N.V. Methods for treating disruptive behavior disorders
WO2008095221A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
BRPI0810161A2 (pt) 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
MX2009012716A (es) 2007-06-05 2009-12-14 Nsab Af Neurosearch Sweden Ab Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical.
CN101765428A (zh) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 多巴胺稳定剂的用途
US8492372B2 (en) * 2008-04-29 2013-07-23 Integrated Research Laboratories Sweden Ab Modulators of dopamine neurotransmission
JP5514804B2 (ja) * 2008-04-29 2014-06-04 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
US20110105462A1 (en) * 2008-04-29 2011-05-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
EP2461673A4 (de) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc Neue regulatorproteine und hemmer
US9273027B2 (en) 2010-02-24 2016-03-01 Research Triangle Institute Arylpiperazine opioid receptor antagonists
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
KR20140008297A (ko) * 2010-09-03 2014-01-21 아이백스 인터내셔널 게엠베하 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
DK2618826T3 (en) 2010-09-20 2016-08-01 A Carlsson Res Ab Phenylpiperdine FOR TREATMENT OF DEMENTIA
ES2639052T3 (es) 2011-09-07 2017-10-25 Teva Pharmaceuticals International Gmbh Forma polimórfica de hidrocloruro de pridopidina
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
CA2879020C (en) 2012-07-12 2021-02-09 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of tourette's syndrome
BR112015006093A2 (pt) * 2012-09-27 2017-07-04 Teva Pharma combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3010506B1 (de) 2013-06-21 2021-05-12 Prilenia Neurotherapeutics Ltd. Pridopidin in der behandlung der huntington-krankheit
DK3057595T3 (da) * 2013-10-18 2020-08-10 Emalex Biosciences Inc Smeltebenzazepiner til behandling af stammen
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA2982898C (en) * 2015-05-13 2023-08-29 A. Carlsson Research Ab Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) * 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
DK3503890T3 (da) * 2016-08-24 2025-01-27 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af dystonier
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
US20200375966A1 (en) 2016-09-15 2020-12-03 Prilenia Therapeutics Development Ltd Use of pridopidine for the treatment of anxiety and depression
ES2909557T3 (es) * 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
JP7114604B2 (ja) 2017-01-20 2022-08-08 プリレニア ニューロセラピューティクス リミテッド 脆弱ｘ症候群の治療のためのプリドピジンの使用
EP3357909A1 (de) 2017-02-02 2018-08-08 Sandoz AG Kristalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidin
MX2020001836A (es) 2017-08-14 2020-08-10 Prilenia Neurotherapeutics Ltd Metodo para tratar esclerosis lateral amiotrofica con pridopidina.
MX2020002310A (es) 2017-08-30 2020-09-17 Prilenia Neurotherapeutics Ltd Formas de dosificacion de alta concentracion de pridopidina.
AU2018329628B2 (en) * 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
AU2020218158B2 (en) 2019-02-04 2023-08-03 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
CA3232827A1 (en) * 2021-09-25 2023-03-30 Paul Daley Substituted phenylalkylamines
JP2025515015A (ja) * 2022-05-03 2025-05-13 プリレニア ニューロセラピューティクス リミテッド プリドピジンを製造するための方法及び中間体
JPWO2024172156A1 (de) * 2023-02-16 2024-08-22

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
US3324916A (en) * 1964-04-09 1967-06-13 Saeki Susumu Rubber rolls for rubbing unhulled rice
BE662455A (de) 1964-04-14
GB1060160A (en) * 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
FR1459013A (fr) 1964-08-05 1966-04-29 Allen & Hanburys Ltd Procédé de préparation de dérivés de la 4-phényl-pipéridine
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ZA7546B (en) * 1974-01-21 1976-08-25 Parke Davis & Co New antibacterial amide compounds and methods for their production
GB1560271A (en) * 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) * 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2429212A1 (fr) * 1978-06-20 1980-01-18 Synthelabo Derives de phenylpiperazine et leur application en therapeutique
FR2459797A2 (fr) * 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4267328A (en) * 1978-08-01 1981-05-12 Synthelabo 1-Phenylpiperazines
US4333942A (en) * 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
SE446335B (sv) * 1982-03-30 1986-09-01 Astra Laekemedel Ab Ren enantiomer av en metasubstituerad 3-fenyl-1-propylpiperidin
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) * 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
ATE50987T1 (de) * 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) * 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
AU7162791A (en) * 1989-12-27 1991-07-24 Miroslav Radman Novel system for isolating and producing new genes, gene products and dna sequences
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ATE201669T1 (de) * 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
RU2052456C1 (ru) * 1991-06-27 1996-01-20 Научно-исследовательский институт фармакологии РАМН Гидрохлорид 3-метил-n-[2-( 4′ -фенилпиперазино)этил]бензамида, обладающий нейролептической активностью, и 3-метил-n-[2-(4-фенилпиперазино)этил]бензамид в качестве исходного соединения для его синтеза
AU676993B2 (en) * 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
PT533268E (pt) 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
CN1036395C (zh) * 1992-03-19 1997-11-12 约翰韦恩兄弟有限公司 哌嗪衍生物的制备方法
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
AU6470096A (en) 1995-07-19 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused triazole compounds
US5892041A (en) * 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) * 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
JP2001526643A (ja) * 1997-04-18 2001-12-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
ES2257864T3 (es) * 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligandos para metales y procesos mejorados catalizados por metales basados en los mismos.
US6232326B1 (en) * 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
AU777961B2 (en) 1999-06-22 2004-11-04 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
EP1313477A4 (de) 2000-07-15 2004-03-03 Smithkline Beecham Corp Zusammenstellungen und methoden
ATE302773T1 (de) 2001-01-23 2005-09-15 Lilly Co Eli Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
ATE449070T1 (de) * 2004-06-08 2009-12-15 Nsab Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission

Also Published As

Publication number Publication date
JP2011236214A (ja) 2011-11-24
PL205093B1 (pl) 2010-03-31
EP1240142A1 (de) 2002-09-18
NO323436B1 (no) 2007-05-07
RU2005117612A (ru) 2006-11-20
HK1054229A1 (en) 2003-11-21
HRP20050784A2 (en) 2006-02-28
RU2002119416A (ru) 2004-01-10
EP1240142B1 (de) 2005-10-19
EP1428822A3 (de) 2009-07-01
NO20022878D0 (no) 2002-06-17
BR0016611A (pt) 2002-09-03
IL150351A (en) 2008-12-29
MXPA02006320A (es) 2004-05-14
WO2001046144A1 (en) 2001-06-28
KR20020067566A (ko) 2002-08-22
DK1240142T3 (da) 2006-02-06
EP1240141B1 (de) 2003-11-19
JP4975928B2 (ja) 2012-07-11
CZ20022070A3 (cs) 2002-10-16
EE05135B1 (et) 2009-02-16
BR0016611B1 (pt) 2012-12-11
ES2208461T3 (es) 2004-06-16
CA2394602C (en) 2009-03-10
AU2570501A (en) 2001-07-03
JP2003518095A (ja) 2003-06-03
RU2265013C2 (ru) 2005-11-27
US6903120B2 (en) 2005-06-07
ZA200204812B (en) 2003-10-29
BG106841A (bg) 2003-01-31
CA2394602A1 (en) 2001-06-28
UA73338C2 (uk) 2005-07-15
WO2001046145A1 (en) 2001-06-28
AU778422B2 (en) 2004-12-02
NZ519595A (en) 2004-05-28
CN1420869A (zh) 2003-05-28
HK1091482A1 (en) 2007-01-19
HRP20020540A2 (en) 2004-12-31
AU2570401A (en) 2001-07-03
NO324874B1 (no) 2007-12-27
US20030139423A1 (en) 2003-07-24
EP1428822A2 (de) 2004-06-16
EE200900004A (et) 2009-04-15
NZ531680A (en) 2005-10-28
ES2246926T3 (es) 2006-03-01
DE60023345T2 (de) 2006-05-24
US20030109532A1 (en) 2003-06-12
HU229605B1 (en) 2014-02-28
IL150351A0 (en) 2002-12-01
WO2001046144A8 (en) 2001-10-04
KR100690133B1 (ko) 2007-03-12
NO20065825L (no) 2001-06-25
ATE254601T1 (de) 2003-12-15
HUP0203872A3 (en) 2005-03-29
CN1255382C (zh) 2006-05-10
KR100779288B1 (ko) 2007-11-27
NO20022878L (no) 2002-08-21
ATE307113T1 (de) 2005-11-15
PL362253A1 (en) 2004-10-18
DE60045395D1 (de) 2011-01-27
BG110211A (en) 2009-02-27
HUP0203872A2 (hu) 2003-03-28
HK1054229B (zh) 2006-09-22
BG65854B1 (bg) 2010-03-31
EE200200344A (et) 2003-06-16
CN1765890A (zh) 2006-05-03
SK8672002A3 (en) 2003-03-04
CZ303302B6 (cs) 2012-07-25
US20060135531A1 (en) 2006-06-22
CN100345833C (zh) 2007-10-31
SK287367B6 (sk) 2010-08-09
DE60006717T2 (de) 2004-08-12
IL186448A0 (en) 2008-01-20
EP1428822B1 (de) 2010-12-15
EP1240141A1 (de) 2002-09-18
SE9904724D0 (sv) 1999-12-22
KR20060006979A (ko) 2006-01-20
JP2009007358A (ja) 2009-01-15
US7417043B2 (en) 2008-08-26
RU2386623C2 (ru) 2010-04-20
SI1240142T1 (sl) 2006-02-28
JP5542740B2 (ja) 2014-07-09
HRP20020540B1 (hr) 2007-12-31
ATE491697T1 (de) 2011-01-15
DE60023345D1 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
ATE307113T1 (de) Neue modulatoren der dopamin-neurotransmission
EP1419773A3 (de) 4-Phenylpiperidin-Derivate als Modulatoren der Dopamin-Neurotransmission
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
AR047557A1 (es) Compuestos derivados de piridazina y su uso como agentes terapeuticos
ATE163648T1 (de) Indole derivate als serotonin-antagonisten
NO990671D0 (no) Muskarinantagonistiske etere
MY133992A (en) Muscarinic antagonists
NO180632C (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
NZ333513A (en) 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
NZ528997A (en) Sulfonamides
PT992509E (pt) Novos derivados macrolidos
DK0688771T3 (da) Anvendelse af lactamforbindelser som farmaceutiske aktivstoffer
WO2003066621A8 (en) Piperidine derivatives and their use as antagonists of tachykinins
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
NZ335631A (en) Antipsychotic (neuroleptic) piperidine derivatives
DE69315363D1 (de) Amphotere tricyclische Verbindungen als antihistaminische und antiallergische Mittel
ECSP982717A (es) Derivados de d-prolina

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee